RaySearch and IBA to Increase Proton Therapy Precision
News May 23, 2013
RaySearch Laboratories AB and IBA (Ion Beam Applications S.A.) have announced a collaboration agreement to further develop the tools that enable clinicians to better leverage the treatment precision of proton therapy.
This collaboration aims at enhancing the tools in RaySearch’s treatment planning system RayStation® for proton treatment modalities (i.e. Double Scattering, Uniform Scanning, and Pencil Beam Scanning).
It will enable clinicians worldwide to better leverage the power of IBA’s Pencil Beam Scanning in a large variety of clinical conditions.
Olivier Legrain, Chief Executive Officer of IBA, said: “We understand that efficient and robust treatment planning solutions are key for the development of proton therapy in general and of Pencil Beam Scanning in particular. In this matter, IBA’s philosophy is to provide its clinical partners with the best software options through an open architecture. Today we are proud to be able to call RaySearch a partner and add its solutions to our portfolio. This collaboration will further improve proton treatment delivery to reduce side effects and increase quality of cancer care.”
Johan Löf, President and CEO of RaySearch Laboratories AB added: “Proton therapy is a prioritized area for us so we are of course delighted to collaborate with the leading hardware manufacturer in this field. We will now work closely together to further refine the tools in RayStation® for planning proton treatments that are delivered with IBA hardware. Together we will be able to realize the full potential of proton therapy and offer unmatched treatment quality to the clinics and their patients. I believe that this will be highly appreciated by existing RayStation® customers such as WPE in Essen, Germany, as well as other proton centers around the globe.”
IBA and RaySearch are committed to making Proton Therapy, the most accurate cancer treatment, available worldwide.
IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of Proton Therapy.
As of today, IBA teams successfully installed PBS at Massachusetts General Hospital Burr Proton Therapy Center, Boston, MA, USA, University of Pennsylvania Health System Roberts Proton Therapy Center, Philadelphia, PA, USA, CDH Procure’s Proton Therapy Center, Chicago area, USA and Proton Therapy Center, Prague, Czech Republic. These centers are using PBS daily in clinical treatments.
PBS is under installation in 5 more IBA centers. Altogether, 20 IBA centers will be treating with PBS within 2 years.
PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.
The Proton Beam Design module in RaySearch’s treatment planning system RayStation® already contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams.
With input from IBA, RaySearch will now expand the module with, for example, tools for Pencil Beam Scanning techniques and Monte Carlo dose calculations.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018